Study to Evaluate the Efficacy and Safety of DWP16001 in Patients With Type 2 Diabetes Mellitus

Inclusion Criteria: * Patients aged 20 to 80 years * Patients who was diagnosed with type 2 diabetes mellitus at least 8 weeks before * Body Mass Index (BMI) between 20 and 45 kg/㎡ * Patients with 7% ≤ HbA1c ≤ 10% at screening * Subject who has conducted a stable diet and exercise for at least 8 weeks Exclusion Criteria: * Type 1 diabetes mellitus or secondary diabetes * Severe diabetes complications (proliferative diabetic retinopathy, stage 4 or higher nephropathy or severe diabetic neuropathy, diabetic ketoacidosis) * Clinical significantly renal disorders * Creatinine clearance \< 60ml/min (0.84ml/s/㎡) or Glomerular filtration rate(eGFR) \< 60mL/min/1.73 * Severe gastrointestinal disorder * Uncontrolled hypertension (SBP \>180 mmHg or DBP \> 110 mmHg) * History of Acute coronary syndrome, unstable angina, myocardial infarction requiring hospitalization, stroke, transient ischemic attack, severe heart failure (NYHA class III/IV), or heart arrhythmia